Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
Life Sciences analysis: One of the most significant public health reforms has been designed to create what the government describes as a ‘smoke-free...
This week's edition of Life Sciences weekly highlights includes analysis of the timetable for the implementation of the Tobacco and Vapes Act 2026 and...
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its position on microbiome-based medicinal products (MBMPs), encouraging...
The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on its Phase 1, 14-Day Pilot Programme, which is intended to...
This week's edition of Life Sciences weekly highlights includes news that the International Medical Device Regulators Forum (IMDRF) has published...
A worldwide problem, for developed and developing countries alike, is the trade of falsified medicinal products. The terms ‘falsified medicines’ and...
This Practice Note tracks the progress of amending legislation, implementing acts, key guidance and initiatives introduced to assist stakeholders in...
Patent systems are intended to foster innovation, not to impede it. For this reason, the patent laws of many jurisdictions contain exemptions to...
In the EU, unilateral or ‘dominant’ firm conduct is governed by Article 102 TFEU. In particular, Article 102 TFEU prohibits undertakings that...
This Practice Note considers exclusion and limitation of liability in business-to-business (B2B) contracts. It provides guidance on the common law and...
This Agreement is made on [insert date]Parties1[Name of Company], a company incorporated in England and Wales with registered number [insert company...
This Agreement is made on [insert date]Parties1[Name of Company], a company incorporated in England and Wales with registered number [insert company...
[insert address of trade mark proprietor]Our ref: [insert reference]Your ref: [insert reference][insert address of recipient][insert date]Dear [insert...
This Agreement is made on [insert date].Parties1[Insert name of first co-owner of patent][ (Company Number [insert number])] [whose [registered office...
This Agreement is made on [insert date]parties1[insert name of manufacturer ][of OR a company incorporated in [England and Wales] under number [insert...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
Generally, active devices refer to medical devices powered by electricity or any source of power other than that generated by the human body or gravity. Examples are examination lights, surgical microscopes, gas pressure regulators or blood pumps for heart-lung machines or devices for viewing diagnostic images such as ultrasound images. Under Regulation (EU) 2017/745 (EU MDR), ‘active device means any device, the operation of which depends on a source of energy other than that generated by the human body for that purpose, or by gravity, and which acts by changing the density of or converting that energy. Devices intended to transmit energy, substances or other elements between an active device and the patient, without any significant change, shall not be deemed to be active devices. Software shall also be deemed to be an active device’. UK legislation compounds the definition of an ‘active’ device with implantable devices.
Animal testing refers to the use of live animals in experiments or procedures for scientific, medical, cosmetic, educational or regulatory purposes, often in the context of product safety or biomedical research. In UK law, the practice is primarily regulated by the Animals (Scientific Procedures) Act 1986 (ASPA), which requires a project licence, personal licence and establishment licence, and imposes controls on the care, use, pain relief and euthanasia of “protected animals”. The concept overlaps with statutory terms such as “regulated procedures” under ASPA.
In Ireland, animal testing is governed by legislation implementing Directive 2010/63/EU, with a similar licensing and inspection regime, and parallel concepts such as “procedures” on protected animals. Across England & Wales, Scotland, Northern Ireland and Ireland, animal testing law is underpinned by the Three Rs (replacement, reduction, refinement) and engages administrative, criminal and regulatory law.
The term is significant in advising on compliance, challenging or defending enforcement action, drafting research protocols, procurement and ethics policies, judicial review of licensing decisions, and navigating overlapping regimes on medicines, chemicals, veterinary products and cosmetics.
Refers to the data exclusivity period granted by Article 10(1) of Directive 2001/83/EC, in which pre-clinical and clinical trial data generated and used to support the authorisation of an innovative medicinal product cannot be referred to by an applicant for a marketing authorisation for a generic product.